UroGen Pharma (NASDAQ:URGN) Earns Sector Outperform Rating from Analysts at Scotiabank

Investment analysts at Scotiabank assumed coverage on shares of UroGen Pharma (NASDAQ:URGN) in a research note issued to investors on Wednesday, Marketbeat.com reports. The firm set a “sector outperform” rating and a $23.00 price target on the stock. Scotiabank’s price target would suggest a potential upside of 137.85% from the stock’s current price.

A number of other research firms have also commented on URGN. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of UroGen Pharma in a report on Monday, March 10th. LADENBURG THALM/SH SH assumed coverage on UroGen Pharma in a research report on Wednesday, February 19th. They set a “buy” rating and a $31.00 price target on the stock. Finally, HC Wainwright cut their price objective on shares of UroGen Pharma from $64.00 to $55.00 and set a “buy” rating for the company in a research report on Tuesday, March 11th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $32.86.

UroGen Pharma Trading Down 6.9 %

Shares of URGN opened at $9.67 on Wednesday. UroGen Pharma has a fifty-two week low of $8.94 and a fifty-two week high of $20.70. The business has a 50-day moving average of $10.50 and a 200 day moving average of $11.21. The firm has a market cap of $445.73 million, a P/E ratio of -3.07 and a beta of 0.80. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00.

UroGen Pharma (NASDAQ:URGN) last posted its earnings results on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The firm had revenue of $24.57 million for the quarter, compared to analysts’ expectations of $25.25 million. As a group, research analysts forecast that UroGen Pharma will post -3.12 EPS for the current year.

Insider Buying and Selling at UroGen Pharma

In related news, General Counsel Jason Drew Smith sold 7,379 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the transaction, the general counsel now directly owns 26,468 shares of the company’s stock, valued at approximately $294,853.52. This trade represents a 21.80 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Mark Schoenberg sold 4,551 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the sale, the insider now directly owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. This represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On UroGen Pharma

A number of hedge funds have recently made changes to their positions in URGN. KLP Kapitalforvaltning AS bought a new position in shares of UroGen Pharma during the 4th quarter valued at $59,000. Lazard Asset Management LLC bought a new position in shares of UroGen Pharma during the fourth quarter valued at about $67,000. GAMMA Investing LLC increased its holdings in shares of UroGen Pharma by 6,908.4% in the first quarter. GAMMA Investing LLC now owns 7,499 shares of the company’s stock worth $83,000 after buying an additional 7,392 shares during the period. Aquatic Capital Management LLC bought a new stake in shares of UroGen Pharma in the 4th quarter valued at about $101,000. Finally, BNP Paribas Financial Markets lifted its stake in shares of UroGen Pharma by 221.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after acquiring an additional 5,890 shares during the last quarter. 91.29% of the stock is currently owned by institutional investors.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.